MedTrace Logo

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

NCT06160895 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-10-30

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.

The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.

Conditions

Interventions

DRUG

TQ-A3334 tablets

TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

DRUG

TQ-A3334 placebo tablets

TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-26
Primary Completion
2024-06-24
Completion
2024-08-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06160895 on ClinicalTrials.gov